RAGE and its ligand amyloid beta promote retinal ganglion cell loss following ischemia-reperfusion injury

Introduction Glaucoma is a progressive neurodegenerative disease associated with age. Accumulation of amyloid-beta (Ass) proteins in the ganglion cell layer (GCL) and subsequent retinal ganglion cell (RGC) loss is an established pathological hallmark of the disease. The mechanism through which Ass provokes RGC loss remains unclear. The receptor for the advanced glycation end product (RAGE), and its ligand Ass, have been shown to mediate neuronal loss via internalizing Ass within the neurons. In this study, we investigated whether the RAGE-Ass axis plays a role in RGC loss in experimental glaucoma. Methods Retinal ischemia was induced by an acute elevation of intraocular pressure in RAGE(-/-) and wild-type (WT) control mice. In a subset of animals, oligomeric Ass was injected directly into the vitreous of both strains. RGC loss was assessed using histology and biochemical assays. Baseline and terminal positive scotopic threshold (pSTR) were also recorded. Results Retinal ischemia resulted in 1.9-fold higher RGC loss in WT mice compared to RAGE(-/-) mice (36 +/- 3% p < 0.0001 vs. 19 +/- 2%, p = 0.004). Intravitreal injection of oligomeric Ass resulted in 2.3-fold greater RGC loss in WT mice compared to RAGE(-/-) mice, 7-days post-injection (55 +/- 4% p = 0.008 vs. 24 +/- 2%, p = 0.02). We also found a significant decline in the positive scotopic threshold response (pSTR) amplitude of WT mice compared to RAGE(-/-) (36 +/- 3% vs. 16 +/- 6%). Discussion RAGE(-/-) mice are protected against RGC loss following retinal ischemia. Intravitreal injection of oligomeric Ass accelerated RGC loss in WT mice but not RAGE(-/-). A co-localization of RAGE and Ass, suggests that RAGE-Ass binding may contribute to RGC loss.